Tideglusib, a non-ATP active GSK-3β antagonist, reduced tau phosphorylation, diminished Aβ accumulation, the proliferation of astrocytes, and cognitive defects in an in vivo AD model [44]. Here, MAPT is linked to Alzheimer disease.